17β-Estradiol, Drosperinone, and UDCA Effective in Cholestasis in Early Postmenopausal Syndrome

Abstract

The aim of the study is to evaluate the effectiveness of menopausal hormone therapy (MHT) in combination with Ursodeoxycholic acid (UDCA) in patients with menopause syndrome in combination with cholestasis to prevent metabolic complications. Materials and methods: 47 patients with menopause syndrome and cholestasis were monitored. Assessment of the patient’s condition was made during four visits. Collection of clinical and anamnestic data, appointment of examination were performed during the 1-st visit. Second visit - assessment of examination results, assessment of inclusion and exclusion criteria, questionnaire survey, prescription of therapy. At the 3rd and 4th visits 3 (12 weeks and 24 weeks ± 3 days after the second visit), the dynamics of clinical and laboratory parameters was assessed, and satisfaction and compliance with therapy were also recorded according to the IMPSS scale. Results and discussion: The findings suggest that 1 mg of 17-estradiol and 2 mg of drospirenone in combination with Ursodeoxycholic acid have an effective cupping of symptoms of menopause syndrome, while normalizing the lipid profile of patients, having a positive effect on the hepatobiliary system. Conclusion. The results of the study showed that the patients have problems with estrogendeficiency conditions characteristic of MS in early postmenopausal period. An important factor that reduces the violation of lipid metabolism in patients with menopausal metabolic syndrome and cholestasis is the concomitant administration of UDCA when prescribing MHT for long-term use.